# Vigonvita Life Sciences clinical trials: 39 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 39 trials with Vigonvita Life Sciences as lead sponsor, 12 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Vigonvita Life Sciences: 39 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/vigonvita-life-sciences

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 39
- Recruiting or not yet: 12
- Read on: November 19, 2026

## Trials

The 25 newest of 39, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 10, 2026 | NCT07927218 | Study of Food Effects of VV261 Tablets in Healthy Trial Participants | Vigonvita Life Sciences | Phase 1 | Not yet recruiting | Severe Fever With Thrombocytopenia Syndrome | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07927218) |
| October 29, 2026 | NCT07905352 | A Phase 2 Clinical Study of Simenafil Hydrochloride Tablets in the Treatment of Alzheimer's Disease | Vigonvita Life Sciences | Phase 2 | Not yet recruiting | Alzheimer Disease | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07905352) |
| October 21, 2026 | NCT07885202 | Study of the Safety, Tolerability, Pharmacokinetics of VV147 Tablets in Chinese Healthy Participants. | Vigonvita Life Sciences | Phase 1 | Not yet recruiting | Healthy Participants | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07885202) |
| July 23, 2026 | NCT07722780 | Evaluate the Efficacy and Safety of VV913 Capsules in the Treatment of PE | Vigonvita Life Sciences | Phase 2 | Not yet recruiting | Premature Ejaculation | 500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07722780) |
| July 17, 2026 | NCT07710326 | Safety and Pharmacokinetics Study of Multiple Ascending Doses of VV261 Tablets | Vigonvita Life Sciences | Phase 1 | Recruiting | Healthy Volunteers | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07710326) |
| July 15, 2026 | NCT07703956 | Evaluating Safety and Efficacy of VV119 in Acute Schizophrenia Adults | Vigonvita Life Sciences | Phase 2 | Not yet recruiting | Schizophrenia | 500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07703956) |
| May 4, 2026 | NCT07565792 | Study of Food Effects of VV913 Capsules in Chinese Healthy Volunteers | Vigonvita Life Sciences | Phase 1 | Recruiting | Healthy Volunteers | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07565792) |
| April 2, 2026 | NCT07507838 | Safety and Pharmacokinetics Study of Multiple Ascending Doses of VV913 Capsules | Vigonvita Life Sciences | Early phase 1 | Recruiting | Healthy Volunteers | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07507838) |
| January 28, 2026 | NCT07372703 | Study of the Safety, Tolerability, Pharmacokinetics of VV913 Capsules in Chinese Healthy Participants | Vigonvita Life Sciences | Phase 1 | Recruiting | Healthy Volunteers | 56 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07372703) |
| December 24, 2025 | NCT07302269 | Study of the Safety, Tolerability, Pharmacokinetics of VV261 Tablets in Chinese Healthy Volunteers | Vigonvita Life Sciences | Phase 1 | Completed | Healthy Volunteers | 66 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07302269) |
| November 21, 2025 | NCT07240636 | Study of Food Effects of VV119 Capsules in Chinese Healthy Volunteers | Vigonvita Life Sciences | Phase 1 | Recruiting | Healthy Volunteers | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07240636) |
| February 17, 2025 | NCT06828887 | Dose-Finding Clinical Trial to Evaluate the Efficacy and Safety of LV232 Capsules in the Treatment of MDD | Vigonvita Life Sciences | Phase 2 | Recruiting | MDD | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06828887) |
| December 27, 2024 | NCT06749236 | A Study to Evaluate the Bioavailability of Two Specifications of Oral Deuremidevir Hydrobromide for Suspension | Vigonvita Life Sciences | Phase 1 | Completed | Healthy Participants | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06749236) |
| July 16, 2024 | NCT06504290 | Evaluating Safety, Tolerability and Pharmacokinetic of Multiple Ascending Doses of VV119 | Vigonvita Life Sciences | Phase 1 | Recruiting | Schizophrenia | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06504290) |
| June 26, 2024 | NCT06476509 | A Study to Assess Serotonin Transporter Occupancy of Healthy Adults Using 11C-DASB PET | Vigonvita Life Sciences | Phase 1 | Completed | Major Depressive Disorder | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06476509) |
| March 25, 2024 | NCT06328400 | A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral Deuremidevir Hydrobromide for Suspension | Vigonvita Life Sciences | Phase 1 | Completed | Respiratory Syncytial Virus Infections | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06328400) |
| March 8, 2024 | NCT06301854 | Long-term Safety of TPN171H Tablet in Erectile Dysfunction. | Vigonvita Life Sciences | Phase 3 | Completed | Erectile Dysfunction | 472 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06301854) |
| February 28, 2024 | NCT06279533 | Safety and Pharmacokinetics Study of Multiple Ascending Doses and Food Effect of LV232 Capsules | Vigonvita Life Sciences | Phase 1 | Completed | Healthy Subjects | 49 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06279533) |
| January 16, 2024 | NCT06206720 | A Study of Deuremidevir Hydrobromide for Suspension in Chinese Infants Hospitalized With RSV | Vigonvita Life Sciences | Phase 2 | Completed | Respiratory Syncytial Virus Infection | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06206720) |
| October 27, 2023 | NCT06105151 | Study of the Safety, Tolerability, Pharmacokinetics and Food Effects of VV119 Capsules in Chinese Healthy Volunteers | Vigonvita Life Sciences | Phase 1 | Active not recruiting | Schizophrenia | 82 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06105151) |
| October 19, 2023 | NCT06090136 | Safety and Pharmacokinetics of a Single Oral TPN171H in Healthy Elderly Subjects | Vigonvita Life Sciences | Phase 1 | Completed | Erectile Dysfunction | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06090136) |
| October 19, 2023 | NCT06090123 | Drug-Drug Interaction (DDI) Study for TPN171H | Vigonvita Life Sciences | Phase 1 | Completed | Erectile Dysfunction | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06090123) |
| October 6, 2023 | NCT06070857 | Study of the Safety, Tolerability, and Pharmacokinetics of LV232 Capsules in Chinese Healthy Volunteers | Vigonvita Life Sciences | Phase 1 | Completed | Healthy Subjects | 81 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06070857) |
| July 17, 2023 | NCT05948644 | The Safety, Tolerability, and Pharmacokinetics of TPN171H Tablets in Patients With Pulmonary Arterial Hypertension | Vigonvita Life Sciences | Phase 1 | Completed | Pulmonary Arterial Hypertension | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05948644) |
| July 6, 2023 | NCT05932459 | A Study to Evaluate the Bioavailability, Food Effect and Pharmacokinetics of Deuremidevir Hydrobromide for Suspension | Vigonvita Life Sciences | Phase 1 | Completed | Healthy Subjects | 38 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05932459) |

## By phase

| Phase | Trials |
| --- | --- |
| Early phase 1 | 1 |
| Phase 1 | 27 |
| Phase 2 | 8 |
| Phase 3 | 3 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 26 |
| Recruiting | 7 |
| Not yet recruiting | 5 |
| Active not recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Erectile Dysfunction | 10 |
| Pulmonary Arterial Hypertension | 4 |
| Schizophrenia | 3 |
| Respiratory Syncytial Virus Infections | 2 |
| Severe Fever with Thrombocytopenia Syndrome | 1 |
| Depressive Disorder, Major | 1 |
| Renal Insufficiency | 1 |
| Premature Ejaculation | 1 |
| COVID-19 | 1 |
| Alzheimer Disease | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Vegan restaurants in the United States](https://specstream.ai/data/businesses/vegan-restaurants/united-states)
- [Medical law firms in the United States](https://specstream.ai/data/businesses/medical-law-firms/united-states)
- [Cosmetic products manufacturers in the United States](https://specstream.ai/data/businesses/cosmetic-products-manufacturers/united-states)
- [Tex-Mex restaurants in the United States](https://specstream.ai/data/businesses/tex-mex-restaurants/united-states)
- [Landscaping companies in the United States](https://specstream.ai/data/businesses/landscaping-companies/united-states)
- [Chicken wings restaurants in the United States](https://specstream.ai/data/businesses/chicken-wings-restaurants/united-states)
